Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Long-Term Deferred Tax (2020 - 2023)

Maravai Lifesciences Holdings (MRVI) has 4 years of Long-Term Deferred Tax data on record, last reported at $773.7 million in Q3 2023.

  • For Q3 2023, Long-Term Deferred Tax changed 0.33% year-over-year to $773.7 million; the TTM value through Sep 2023 reached $773.7 million, changed 0.33%, while the annual FY2022 figure was $765.8 million, 5.24% down from the prior year.
  • Long-Term Deferred Tax reached $773.7 million in Q3 2023 per MRVI's latest filing, up from $769.6 million in the prior quarter.
  • Across five years, Long-Term Deferred Tax topped out at $820.8 million in Q3 2021 and bottomed at $419.9 million in Q1 2021.
  • Average Long-Term Deferred Tax over 4 years is $705.9 million, with a median of $770.4 million recorded in 2022.
  • The widest YoY moves for Long-Term Deferred Tax: up 88.9% in 2022, down 6.05% in 2022.
  • A 4-year view of Long-Term Deferred Tax shows it stood at $431.7 million in 2020, then skyrocketed by 87.19% to $808.1 million in 2021, then decreased by 5.24% to $765.8 million in 2022, then grew by 1.03% to $773.7 million in 2023.
  • Per Business Quant database, its latest 3 readings for Long-Term Deferred Tax were $773.7 million in Q3 2023, $769.6 million in Q2 2023, and $767.0 million in Q1 2023.